Related Experiment Video
Updated: Oct 1, 2025
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.5K
Prevention of chemotherapy-induced left ventricular dysfunction
Irma Bisceglia1, Maria Laura Canale2, Domenico Cartoni1
1UOSD Servizi Cardiologici Integrati (SCI), A.O. S. Camillo-Forlanini, Roma, Italy.
Summary
Preventing heart dysfunction from cancer drugs like anthracyclines and trastuzumab is crucial. Early risk assessment and managing heart health factors are key to effective cardioprotection strategies.
Area of Science:
- Cardio-oncology
- Cardiovascular Medicine
- Cancer Therapeutics
Background:
- Left ventricular dysfunction is a significant challenge in cardio-oncology, often induced by anthracyclines and/or trastuzumab.
- This cardiotoxicity can limit the survival benefits gained from cancer treatments.
- Current preventive strategies require refinement to effectively manage this risk.
Purpose of the Study:
- To review current strategies for preventing anthracycline and/or trastuzumab-induced left ventricular dysfunction.
- To emphasize the importance of baseline cardiovascular risk assessment and management.
- To highlight the need for identifying high-risk populations and genetically predisposed individuals for targeted cardioprotection.
Main Methods:
- Review of existing oncology strategies for mitigating cardiotoxicity, including dose limitation and specific drug formulations.
- Evaluation of the evidence for preventive use of medications such as ACE inhibitors, sartans, and beta-blockers.
- Discussion of baseline cardiovascular risk assessment and management of modifiable risk factors.
Main Results:
- Certain oncology strategies (dose limitation, dexrazoxane, liposomal formulations) can reduce anthracycline cardiotoxicity.
- Preventive use of ACE inhibitors, sartans, and beta-blockers has shown limited clinical relevance for left ventricular ejection fraction decline.
- Baseline cardiovascular risk assessment and control of modifiable factors are essential primary prevention steps.
Conclusions:
- Effective prevention of cancer therapy-induced cardiotoxicity requires a multi-faceted approach.
- Identifying high-risk and genetically susceptible patients is crucial for implementing timely and appropriate cardioprotective therapies.
- Further research is needed to optimize preventive strategies in cardio-oncology.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
55
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
55
01:22Heart Failure VI: Adjunct Therapies
47
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
01:30Cardiomyopathy II: Dilated Cardiomyopathy
47
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
547
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
547
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
45
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
45
01:29Cardiomyopathy VI: Nursing Management
64
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
64